v3.26.1
Segment Information - Schedule of Segment Information (Details) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Significant components of general and administrative (G&A) expenses:        
Total operating expenses $ 9,379 $ 4,651 $ 18,660 $ 9,672
Loss from operations (9,379) (4,651) (18,660) (9,672)
Total other income (expense), net 38 (565) 76 (255)
Income tax expense (101) (61) (101) (61)
Net loss (9,442) (5,277) (18,685) (9,988)
Reportable Segment        
Significant components of research and development (R&D) expenses:        
Clinical trial expenses 1,056 422 1,803 792
Manufacturing and related process development expenses 413 425 920 839
Personnel-related expenses 2,699 1,045 5,970 3,026
Significant components of general and administrative (G&A) expenses:        
Public company-related expenses 3,368 1,580 6,384 2,780
Personnel-related expenses 1,371 888 2,601 1,625
Intellectual property expenses 149 85 451 192
All other R&D and G&A expenses 323 206 531 418
Total operating expenses 9,379 4,651 18,660 9,672
Loss from operations (9,379) (4,651) (18,660) (9,672)
Total other income (expense), net 38 (565) 76 (255)
Income tax expense (101) (61) (101) (61)
Net loss $ (9,442) $ (5,277) $ (18,685) $ (9,988)